News - Diabetes


Current filters:


Popular Filters

126 to 150 of 436 results

Vivus obesity drug reduces progression to type 2 diabetes in high-risk overweight patients


New data published on-line in Diabetes Care, today Care demonstrating positive effects of USA-based Vivus’…


Case study draws attention to innovator brand preferences in Kenya


Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

Evolva to license EV-077 to Serodus


Switzerland-based Evolva Holding and Norwegian biopharma company Serodus have signed a binding term…

BiotechnologyDiabetesEV-077EvolvaLicensingNephrology and HepatologyPharmaceuticalSerodus

Lyxumia plus basal insulin lowers blood sugar, latest data show

Lyxumia plus basal insulin lowers blood sugar, latest data show


Sanofi has announced new GetGoal-L sub-analysis results showing that reductions in HbA1c with Lyxumia…

DiabetesLyxumiaPharmaceuticalResearchSanofiZealand Pharma

DPP-IV inhibitors use in newly-diagnosed type 2 diabetes patients


Through analysis of US longitudinal patient-level claims data, dipeptidyl peptidase (DPP-IV) inhibitors…

DiabetesMarkets & MarketingNorth AmericaPharmaceutical

New hypoglycemia and pancreatitis sub-analyses from the Onglyza SAVOR study released at EASD

New hypoglycemia and pancreatitis sub-analyses from the Onglyza SAVOR study released at EASD


Bristol-Myers Squibb and partner AstraZeneca have announced additional results from the SAVOR cardiovascular…

AstraZenecaBristol-Myers SquibbDiabetesOnglyzaPharmaceuticalResearch

Sanofi strengthens its presence in Algeria with €70 million investment

Sanofi strengthens its presence in Algeria with €70 million investment


French drug major Sanofi revealed today that construction has begun on its new Sidi Abdellah industrial…

Cardio-vascularDiabetesFinancialPharmaceuticalProductionRest of the WorldSanofi

Geropharm to invest $45 million in Russian insulin production

Geropharm to invest $45 million in Russian insulin production


Geropharm, one of Russia’s leading pharmaceutical and biotech companies, is establishing a plant for…

DiabetesEli LillyEuropeFinancialGeropharmNovo NordiskPharmaceuticalProductionSanofi

Takeda’s Vipidia for type 2 diabetes gets go-ahead in Europe

Takeda’s Vipidia for type 2 diabetes gets go-ahead in Europe


Japan’s largest drugmaker Takeda Pharmaceutical has received marketing authorization from the European…


UK CDMO Aesica unveils a new £30m high capacity manufacturing facility


UK contract development and manufacturing organization (CDMO) Aesica Pharmaceuticals has announced the…

Aesica PharmaceuticalsDiabetesEuropePharmaceuticalProduction

Approved cancer drug potentially could help treat diabetes, Stanford researchers find


A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular…


Pilot project in Ukraine for regulation of insulin preparation pricing


Last week in the Ukraine, the Association of Pharmaceutical Research and Development (APRaD) and the…


Indication changes for Glufast approved in Japan


Japanese drugmakers Kissei Pharmaceutical (TYO: 4547) and Takeda Pharmaceutical (TYO: 4502) have received…

Asia-PacificDiabetesGlufastKissei PharmaceuticalPharmaceuticalRegulationTakeda Pharmaceuticals

Sanofi temporarily pulls lixisenatide NDA in USA


French drug major Sanofi (Euronext: SAN) this morning (September 12) announced its decision to withdraw…

DiabeteslixisenatideLyxumiaNorth AmericaPharmaceuticalRegulationSanofiZealand Pharma

Interim results for ChemoCentryx' CCX140 fail to inspire


US drug developer ChemoCentryx (Nasdaq: CCXI) announced interim data from an ongoing Phase II study in…

BiotechnologyCCX140ChemoCentryxDiabetesNephrology and HepatologyResearch

Depomed expands geographic scope of metformin deal with Merck


USA-based Depomed (Nasdaq: DEPO) says it has expanded the geographic scope of its non-exclusive license…

DepomedDiabetesJanumetLicensingMerck & CometforminPharmaceutical

ThromboGenics gains rights to DME drug


Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR:BR) has entered into a collaboration…

Bicycle TherapeuticsBiotechnologyDiabetesLicensingOphthalmicsPharmaceuticalThromboGenics

Novo Nordisk falls on loss of two US contracts


Danish insulin giant Novo Nordisk (NOV: N) saw its shares fall 2.8% to 936 Danish kroner yesterday (September…

Bristol-Myers SquibbDiabetesEli LillyMarkets & MarketingNorth AmericaNovo NordiskNovoLogPharmaceuticalVictoza

Merck & Co to co-promote diabetes agent ipragliflozin in Japan


Japanese drug major Astellas Pharma (TYO: 4503) has entered into a co-promotion agreement in Japan with…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalLicensingMarkets & MarketingMerck & CoPharmaceutical

Zealand and Lilly to work together on type 2 diabetes and obesity therapies


Denmark's Zealand Pharma (Nasdaq OMX: ZEAL) has announced an exclusive peptide drug R&D collaboration…

DiabetesEli LillyGlobalPharmaceuticalResearchZealand Pharma

126 to 150 of 436 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top